Robeco Institutional Asset Management B.V. Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Robeco Institutional Asset Management B.V. increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 62.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 448,617 shares of the life sciences company’s stock after purchasing an additional 172,111 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.28% of Illumina worth $59,949,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc increased its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC boosted its holdings in Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares during the period. Massmutual Trust Co. FSB ADV grew its position in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. Private Trust Co. NA increased its stake in Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares during the period. Finally, Focused Wealth Management Inc bought a new stake in Illumina in the third quarter valued at approximately $63,000. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $131.72 on Thursday. The business has a fifty day moving average price of $139.05 and a 200-day moving average price of $135.07. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market capitalization of $20.89 billion, a PE ratio of -13.22 and a beta of 1.11. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.33 EPS. As a group, equities analysts expect that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ILMN. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, October 17th. Stephens upped their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Leerink Partners increased their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Royal Bank of Canada boosted their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Finally, Canaccord Genuity Group increased their price objective on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $165.63.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.